Document Detail

Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
MedLine Citation:
PMID:  9474013     Owner:  NLM     Status:  MEDLINE    
Plasma concentrations of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1), and D-dimer were investigated in 50 patients treated intravenously for acute myocardial infarction with either streptokinase (n = 23), urokinase (n = 17), or recombinant t-PA (rt-PA, n = 10). The fibrinolytic variables were measured by enzyme immunoassay on admission; 1, 2, 4, 6, 8, 12, and 24 h later; and then daily until day 7 after admission. In each subgroup of patients treated with different thrombolytic agents, PAI-1 increased significantly (P < 0.01) approximately 3 h after cessation of thrombolytic therapy. PAI-1 peak concentrations did not differ significantly (P = 0.82) among these three subgroups. t-PA and D-dimer did not differ significantly (P > 0.14) among subgroups except for higher t-PA in the rt-PA group attributable to detection of the therapeutically administered exogenous rt-PA by the t-PA assay. Our findings demonstrate a marked PAI-1 increase after thrombolytic therapy for acute myocardial infarction, which seems to be a common, drug-independent antifibrinolytic rebound phenomenon in response to thrombolytic treatment.
N Genser; P Lechleitner; J Maier; F Dienstl; E Artner-Dworzak; B Puschendorf; J Mair
Related Documents :
11824003 - Early myocardial reperfusion: an assessment of current strategies in acute myocardial i...
11401183 - Update on strategies to improve thrombolysis for acute myocardial infarction.
6650773 - Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. a prospective...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Clinical chemistry     Volume:  44     ISSN:  0009-9147     ISO Abbreviation:  Clin. Chem.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-03-16     Completed Date:  1998-03-16     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9421549     Medline TA:  Clin Chem     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  209-14     Citation Subset:  IM    
Department of Internal Medicine, University of Innsbruck, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Creatine Kinase / blood
Fibrin Fibrinogen Degradation Products / analysis
Middle Aged
Myocardial Infarction / drug therapy*
Myoglobin / blood
Plasminogen Activator Inhibitor 1 / metabolism*
Recombinant Proteins / therapeutic use
Streptokinase / therapeutic use
Thrombolytic Therapy*
Tissue Plasminogen Activator / blood,  therapeutic use*
Urokinase-Type Plasminogen Activator / therapeutic use
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/Myoglobin; 0/Plasminogen Activator Inhibitor 1; 0/Recombinant Proteins; 0/fibrin fragment D; EC Kinase; EC 3.4.-/Streptokinase; EC Plasminogen Activator; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by...
Next Document:  A family with high serum leucine aminopeptidase activity derived from a novel variant CD13.